US FDA approves UCB bowel disease drug
WASHINGTON, April 22 (Reuters) - U.S. health officials have approved UCB Inc's (UCB.BR: Quote, Profile, Research, Stock Buzz) experimental drug to treat Crohn's disease, the U.S. Food and Drug Administration said on Tuesday.
The drug, called Cimzia, aims to treat patients with the chronic, inflammatory bowel disease but puts them "at increased risk for serious adverse effects, including serious infections that can lead to hospitalization or death," the FDA said.
Common side effects reported with the drug include headache, upper respiratory infections, abdominal pain and nausea, it added.
(Reporting by Susan Heavey)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Tech Week
Bush: G7 needs coordination